However, anti-4-1BB antibodies have exhibited dose-limiting on-target-off-tumour hepatotoxicity in the clinic [47], which could be mediated through liver macrophages activated by nonspecific hepatic memory CD8+ T cells triggered by anti-4-1BB [48]. The gene discussed is TNFRSF9; the disease is neoplasm.